Shore ND, Fizazi K, Tammela T, Luz M, Salas MP, Ouellette P, Lago S, Bastos DA, Jansz GK, Carcano FM, Andrade L, Pliskin M, Lazaretti N, Arruda L, Correa JJ, Petrenciuc O, Kappeler C, Sarapohja T, Smith MR. Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial. Journal of Clinical Oncology (Genitourinary Cancers Symposium) 2021 39:6_suppl, 240-240